{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellular+Repair+Therapy", "query": { "intervention": "Cellular Repair Therapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 138, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellular+Repair+Therapy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-19T15:44:38.476Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06295159", "title": "Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma Stage III", "Melanoma Stage IV", "Advanced Melanoma", "Melanoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Nivolumab + Relatlimab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2024-05-17", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-09-19T15:44:38.476Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06295159" }, { "nct_id": "NCT05112601", "title": "Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Dedifferentiated Carcinoma", "Endometrial Endometrioid Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Mucinous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Endometrioid Adenocarcinoma", "Recurrent Endometrial Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 81, "start_date": "2022-06-02", "completion_date": "2032-07-30", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-09-19T15:44:38.476Z", "location_count": 138, "location_summary": "Birmingham, Alabama • Athens, Georgia • Augusta, Georgia + 107 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Athens", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Boise", "state": "Idaho" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT05112601" }, { "nct_id": "NCT05609370", "title": "A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer" ], "interventions": [ { "name": "Alcestobart", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Bevacizumab or Bevacizumab biosimilar", "type": "DRUG" }, { "name": "Fluoropyrimidine (FP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2023-01-29", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-09-19T15:44:38.476Z", "location_count": 30, "location_summary": "Anchorage, Alaska • Gilbert, Arizona • Cerritos, California + 23 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05609370" }, { "nct_id": "NCT01851369", "title": "TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphomas", "Solid Tumors", "NSCLC", "Metastatic Colon Carcinoma", "Granulosa Cell Ovarian Cancer" ], "interventions": [ { "name": "TRC102", "type": "DRUG" }, { "name": "CT scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Lomotil", "type": "OTHER" }, { "name": "Prochlorperazine", "type": "OTHER" }, { "name": "Metoclopramide", "type": "OTHER" }, { "name": "5-HT3 antagonist", "type": "OTHER" }, { "name": "Aprepitant", "type": "OTHER" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 93, "start_date": "2013-07-12", "completion_date": "2023-08-01", "has_results": true, "last_update_posted_date": "2024-05-08", "last_synced_at": "2026-09-19T15:44:38.476Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01851369" }, { "nct_id": "NCT02154490", "title": "Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Recurrent Squamous Cell Lung Carcinoma", "Stage IV Squamous Cell Lung Carcinoma AJCC v7" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "FGFR Inhibitor AZD4547", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Rilotumumab", "type": "BIOLOGICAL" }, { "name": "Talazoparib", "type": "DRUG" }, { "name": "Taselisib", "type": "DRUG" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1864, "start_date": "2014-07-08", "completion_date": "2022-04-15", "has_results": true, "last_update_posted_date": "2023-06-01", "last_synced_at": "2026-09-19T15:44:38.476Z", "location_count": 998, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 639 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02154490" }, { "nct_id": "NCT04586452", "title": "NIH CCR2 AAA Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Abdominal Aortic Aneurysm (AAA)", "No Abdominal Aortic Aneurysm (Non-AAA)" ], "interventions": [ { "name": "AAA Group (Aim 3A)", "type": "DIAGNOSTIC_TEST" }, { "name": "Non-AAA Group", "type": "DIAGNOSTIC_TEST" }, { "name": "Ex Vivo Human AAA Specimens (Aim 2A)", "type": "OTHER" }, { "name": "Relationship between radiotracer and CCR2 (Aim 2B)", "type": "OTHER" }, { "name": "AAA Group (Aim 3B-Reproducibility)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 50, "start_date": "2021-02-17", "completion_date": "2022-04-04", "has_results": false, "last_update_posted_date": "2025-07-15", "last_synced_at": "2026-09-19T15:44:38.476Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04586452" }, { "nct_id": "NCT07807085", "title": "Apple Peptide Complex for Post-Surgical and Aesthetic Skin Recovery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Skin Barrier to Water Loss", "Skin Health", "Skin Discoloration", "Skin Irritation", "Skin Abnormalities", "Hyperpigmentation", "Hyperpigmentation; Melanin", "Stretch Mark", "Breast Reconstruction", "Breast Augmentation and Breast Reconstruction", "Chemotherapy Effects", "Lymphatic Abnormalities" ], "interventions": [ { "name": "Apple Peptide Complex Post-Aesthetic Care Protocol", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Grow Out Oils Clinical Aromatherapy Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 50, "start_date": "2021-01-20", "completion_date": "2025-12-29", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-09-19T15:44:38.476Z", "location_count": 1, "location_summary": "Weston, Florida", "locations": [ { "city": "Weston", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07807085" }, { "nct_id": "NCT02983578", "title": "Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Colorectal Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Lung Non-Small Cell Carcinoma", "Mismatch Repair Deficiency", "Refractory Colorectal Carcinoma", "Refractory Lung Carcinoma", "Refractory Pancreatic Carcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2017-03-02", "completion_date": "2025-08-30", "has_results": false, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-09-19T15:44:38.476Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02983578" }, { "nct_id": "NCT00505219", "title": "Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Osteonecrosis" ], "interventions": [ { "name": "Ixmyelocel-T", "type": "BIOLOGICAL" }, { "name": "Standard of Care Only", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Vericel Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 11, "start_date": "2007-09", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2019-10-21", "last_synced_at": "2026-09-19T15:44:38.476Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Minneapolis, Minnesota • Brooklyn, New York", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Brooklyn", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00505219" }, { "nct_id": "NCT02664207", "title": "Extended Criteria For Fetal Myelomeningocele Repair", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity", "Myelomeningocele", "Pregnancy", "Diabetes Mellitus in Pregnancy", "Fetal Anomaly" ], "interventions": [ { "name": "Open Fetal Repair of Myelomeningocele", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "16 Years to 45 Years · Female only" }, "enrollment_count": 12, "start_date": "2016-01-26", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2024-05-08", "last_synced_at": "2026-09-19T15:44:38.476Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02664207" } ] }